The shares of Zosano Pharma Corporation (NASDAQ:ZSAN) has been pegged with a rating of Buy by Maxim Group in its latest research note that was published on April 17, 2019. The Healthcare company has also assigned a $8 price target. Maxim Group wasn’t the only research firm that published a report of Zosano Pharma Corporation, with other equities research analysts also giving their opinion on the stock. Piper Jaffray advised investors in its research note published on March 24, 2017, to Overweight the ZSAN stock while also putting a $4 price target. The stock had earned Neutral rating from Ladenburg Thalmann Markets when it published its report on August 11, 2016. The stock was given Buy rating by ROTH Capital in its report released on November 11, 2015, the day when the price target on the stock was placed at 7. ROTH Capital was of a view that ZSAN is Buy in its latest report on September 29, 2015. ROTH Capital thinks that ZSAN is worth Buy rating. This was contained in the firm’s report on February 23, 2015 in which the stock’s price target was also moved to 20.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 0 believe it has the potential for further growth, thus rating it as Hold while 2 advised investors to purchase the stock. The consensus currently stands at a Buy while its average price target is $9.00. The price of the stock the last time has raised by 44.00% from its 52-Week high price while it is -89.32% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 42.87.
The shares of the company added by 9.40% during the trading session on Wednesday, reaching a low of $0.54 while ending the day at $0.58. During the trading session, a total of 3.04 million shares were traded which represents a 0.95% incline from the average session volume which is 3.07 million shares. ZSAN had ended its last session trading at $0.53. Zosano Pharma Corporation debt-to-equity ratio currently stands at 1.14, while its quick ratio hovers at 0.40 ZSAN 52-week low price stands at $0.41 while its 52-week high price is $5.46.
The Zosano Pharma Corporation generated 6.32 million in revenue during the last quarter. In the second quarter last year, the firm recorded -$0.55 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -71.74%.
Investment analysts at Jefferies published a research note on March 23, 2020 where it informed investors and clients that Valvoline Inc. (NYSE:VVV) is now rated as Hold. Goldman also rated VVV as Upgrade on March 13, 2020, with its price target of $24 suggesting that VVV could surge by 43.82% from its current share price. Even though the stock has been trading at $11.85/share, analysts expect it to surge by 16.96% to reach $24.67/share. It started the day trading at $14.07 and traded between $11.81 and $13.86 throughout the trading session.
A look at its technical shows that VVV’s 50-day SMA is 19.30 while its 200-day SMA stands at 20.94. The stock has a high of $23.90 for the year while the low is $9.06. The stock, however, witnessed a rise in its short on 03/13/20. Compared to previous close which recorded 2.87 M shorted shares, the short percentage went higher by 107.37%, as 5.96M ZSAN shares were shorted. At the moment, only 1.53% of Valvoline Inc. shares were sold short. The company’s average trading volume currently stands at 2.07M shares, which means that the short-interest ratio is just 1.39 days. Over the past seven days, the company moved, with its shift of 34.82%. Looking further, the stock has dropped -35.38% over the past 90 days while it lost -36.48% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The The Vanguard Group, Inc. bought more VVV shares, increasing its portfolio by 0.24% during the last quarter. This move now sees The The Vanguard Group, Inc. purchasing 42,685 shares in the last quarter, thus it now holds 18,030,429 shares of VVV, with a total valuation of $351,593,366. BlackRock Fund Advisors meanwhile bought more VVV shares in the recently filed quarter, changing its stake to $307,623,576 worth of shares.
Similarly, Capital Research & Management Co…. increased its Valvoline Inc. shares by 1.49% during the recently filed quarter. After buying 11,663,237 shares in the last quarter, the firm now controls 171,011 shares of Valvoline Inc. which are valued at $227,433,122. In the same vein, Capital Research & Management Co…. increased its Valvoline Inc. shares by during the most recent reported quarter. The firm bought 8,119 shares during the quarter which increased its stakes to 10,027,755 shares and is now valued at $195,541,223. Following these latest developments, around 0.20% of Valvoline Inc. stocks are owned by institutional investors and hedge funds.